, Parkinson's disease 6, 7 and vascular dementia 8 ; rarer disorders such as frontotemporal dementia 9 and Huntington's disease 10 ; and psychiatric conditions such as major depressive disorder (MDD) 11, 12 and schizophrenia 13, 14 (Box 1).
Several syndromes associated with diminished motivation have been described 15 . Historically, reports of these syndromes arose from diverse medical and psychological experts in the 19th century 16 . Although different terminologies were used for different patient groupssometimes rather loosely and interchangeably -these phenomena are now recognized to overlap greatly.
In neurological disorders, amotivation is typically categorized as the syndrome of apathy, which itself is defined as diminished motivation for physical, cognitive or emotional activity [17] [18] [19] . In psychiatry, although the term apathy has also been used, amotivation is more often referred to in the context of either anhedonia 20 or negative symptoms 21 . Classically, anhedonia was defined by the French psychologist Ribot as an inability to experience pleasure. However, this definition was later broadened in psychiatric diagnostic criteria to include a motivational component -that is, a loss of interest or pleasure in previously rewarding activities 22 . Recent research suggests that there might be some common mechanisms underlying both apathy and anhedonia.
Findings from studies of behaviour, computational models, neuropharmacological or optogenetic manipulations, brain lesions, deep brain stimulation (DBS) and neuroimaging -in humans and in animal models -have identified the brain systems that are dysfunctional in amotivated states. The results implicate disruption of mechanisms underlying the way in which reward is processed to motivate behaviour [22] [23] [24] [25] . In this Review, we explain how, broadly speaking, these mechanisms can be conceptualized within the framework of effort-based decision making for rewards 26, 27 -that is, how the potential benefit or reward for performing an activity is evaluated with respect to the cost in effort required to attain it.
The mechanisms underlying such decision making seem to be affected in people with amotivation associated with different brain disorders, regardless of underlying pathology, suggesting that it might be timely to develop a transdiagnostic approach that cuts across traditional diagnostic boundaries. Here, we examine whether such an approach might indeed be useful by focusing on apathy and anhedonia, and their associated neural and behavioural signatures, across different neurological and psychiatric disorders.
Definitions
Although there has been debate, most experts now consider apathy to be a syndrome. One set of criteria 19 for apathy builds on previous conceptualizations 28, 29 and has been validated across neurological and psychiatric conditions. These criteria define apathy as loss or reduction of motivation compared with an individual's previous state; associated with decreases in at least two out of three of goal-directed behaviour, cognitive activity or emotion; causing clinically significant impairment in everyday life; but not explained by physical or motor disability, reduced consciousness or drugs 19 . However, this definition might not capture all aspects of apathy. For example, recent research has identified social apathy -reduced interest in interacting with other people 30, 31 -as another possible component or dimension of the syndrome. 
Negative symptoms
Thoughts, feelings or behaviours normally present that are absent or diminished.
Some clinicians also use the terms avolition 21 or abulia 16 . People with avolition or abulia encounter difficulty in initiating behaviours but can perform the same actions when verbally prompted to do so. Avolition can be a prominent negative symptom of schizophrenia 21 . An extreme form of avolition is akinetic mutism, which is characterized by little or no self-generated movement or speech 32 . Anhedonia is defined as consistently and markedly diminished interest or pleasure in almost all daily activities. Although originally conceptualized as a lack of pleasurable experience, for several decades psychiatrists have recognized that this symptom may also reflect a loss of interest (that is, the motivation) to act in order to seek pleasure 22 . This distinction is important for recent conceptualizations of amotivational syndromes, which consider anhedonia to share some aspects of apathy. It is also important for animal models of anhedonia, in which affective experiences of pleasure are challenging to measure, but motivation to obtain rewards is far easier to investigate. Similar to apathy, anhedonia might exist for different dimensions, with dissociable axes of loss of interest or pleasure in social activities, sensory experiences, hobbies or food and drink 33 . Fractionation of apathy and anhedonia into components potentially provides a way to examine similarities between the syndromes at a fine-grain level.
Along with depressed mood, anhedonia is one of the cardinal symptoms of MDD. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 34 , patients meet criteria for MDD if they have five or more symptoms, one of which must be either depressed mood or anhedonia. However, anhedonia can occur outside of MDD. For example, it has long been recognized as a negative symptom of schizophrenia, and is increasingly appreciated to be an important component of post-traumatic stress disorder, eating disorders and substance use disorder 35 . Anhedonia and apathy are measured using either questionnaires filled by the patient or caregiver, or a structured interview performed by the clinician (Box 1). The closeness of apathy and anhedonia as syndrome constructs is emphasized by the few studies that have
DSM-IV field trials
Reports on the first attempts to apply the diagnostic criteria laid down in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition in real-world settings.
Avolition
Inability to perform selfdirected, purposeful activities.
Abulia
Reduced spontaneous verbal, motor, cognitive and emotional behaviours.
Akinetic mutism
Loss of ability to self-initiate limb movement and speech.
Box 1 | Measurement and prevalence of apathy and anhedonia
Clinically, apathy and anhedonia are measured using either self-report questionnaires or structured interviews 13, [17] [18] [19] 163 . Popular anhedonia questionnaires 13, 163 include the Scale for Physical Anhedonia and the Scale for Social Anhedonia (which focus on lifetime hedonic responses to specific environmental stimuli), the Snaith-Hamilton Pleasure Scale (which is more general and includes less culturally bound questions, rated over recent days) and the Temporal experience of Pleasure Scale (which attempts to distinguish the hedonic and appetitive components of anhedonia). Several questionnaires for apathy exist, with two commonly used ones being the Apathy evaluation Scale and the Apathy Scale [17] [18] [19] . In interviews, scores are commonly derived using questions from measures such as the Scale for the Assessment of Negative Symptoms in schizophrenia, although such scales usually feature only a small number of items specifically relating to amotivation 13 . However, structured interviews specifically focused on apathy (such as the lille Apathy Rating Scale) and anhedonia (for example, the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale) have been developed 164 . estimates of apathy in neurological disorders vary depending on the scales used and the selection criteria, but some reported mean prevalence rates are shown in the table. Reliable data regarding anhedonia in some of these groups are sparse, largely because studies in neurological disorders focus on apathy. However, in one investigation conducted in Parkinson's disease, almost all patients who were apathetic were also anhedonic, whereas almost one-third of the sample fulfilled criteria for anhedonia without having apathy 165 . Anhedonia is extremely common in depression, with both population-based surveys 166 and DSM-IV field trials 167 suggesting a prevalence of 85-95% in major depressive disorder (mDD), on the basis of responses to a single question. Studies using questionnaires (with cut-offs defined by the authors of the scale) report clinically significant anhedonia in 37% of mDD patients 11 . In schizophrenia, anhedonia has been reported to vary in prevalence from 45% when assessed using questionnaires 11 to ~80% using clinical interviews 13 . Anhedonia and apathy can occur within the same individual, as reported in both schizophrenia 40 and Parkinson's disease 36 . Apathy has a severe impact on the quality of life of both the patient and the carer as well as on functional independence and prognosis 18 . The severity of anhedonia varies greatly within a patient group and correlates with more severe symptoms, poorer treatment response and low self-reported quality of life in depression 39 , and poor functional outcome in schizophrenia 168 .
Disorder

Apathy in population (%) Refs Anhedonia in population (%) Refs
Alzheimer 36 . In schizophrenia, apathy and anhedonia usually cluster together as negative symptoms [37] [38] [39] , and the severity of apathy correlates with scores of anhedonia, avolition or asociality 40 as well as with global negative symptom scores 41 . However, some reports also show that anhedonia -at least in terms of inability to experience pleasure -can be dissociable from apathy (for example, in Parkinson's disease) 42 . These findings demonstrate how important it might be to deconstruct apathy and anhedonia into component processes, rather than to consider them as single, monolithic entities. To the best of our knowledge, such an approach, using either behavioural experimental studies or computational modelling, has not hitherto been used to compare mechanisms underlying both apathy and anhedonia within the same individual or patient group (Box 1).
Aspects of apathy and anhedonia may also be related to two common symptoms: anergia and fatigue. People with anergia complain of feeling sluggish, being drained or lacking strength even without exerting themselves, whereas fatigue refers to tiredness following activity, either physical or mental. It is not uncommon to find patients who articulate lack of motivation in terms of lacking energy or being fatigued. When apathy, anhedonia and fatigue are evaluated concurrently, there are significant positive correlations between all of these symptoms 31 , for example in Parkinson's disease 43 . Furthermore, the Tenth Revision of the International Classification of Diseases (ICD-10) criteria for MDD include fatigue or low energy as a cardinal symptom, in addition to anhedonia and depressed mood.
Anergia and fatigue can also occur in individuals without depression -for example, in systemic illnesses or chronic fatigue syndrome. An important question is whether, in addition to any peripheral muscular factors, there might be central motivational contributions to these symptoms. Similarly, apathy and anhedonia are now recognized to occur not only in the context of clinical diagnoses but also, in milder forms, in the general population, particularly with ageing 44, 45 . This realization has led some researchers to investigate whether there might be a neurobiological basis to these symptoms in otherwise healthy individuals 46 , with ageing [47] [48] [49] or in people at high risk of developing depression 50 . Across several different studies, in young and old people, both structural and functional brain activity changes have been identified [46] [47] [48] [49] [50] , including in frontal and basal ganglia regions identified in patient groups discussed below (see Brain regions below).
Behavioural approaches
Given the importance and clinical impact of disorders of motivation, several paradigms have been developed to examine such behavioural changes in animal models 25 . In turn, some of these have led to analogous tests for humans, including various clinical populations 24 . Broadly speaking, many of the animal-model tasks can be considered to examine one or more of the decision, appetitive, consummatory or learning phases of behaviour, although different authors vary in their classification of these phases 20, 23, 25 . Despite a lack of complete agreement, one area of consensus is that there might be several mechanisms -or combinations of mechanismsthat underlie amotivation in people 51 . This notion has important implications for treatments. Here, we examine apathy and anhedonia using the conceptual framework of mechanisms deployed in effort-based decision making for rewards (FIg. 1) .
Option generation. One important component in effort-based decision making for rewards is the ability to first generate options for behaviour 52 -whether self-generated or cued by environmental stimuli. Many patients with amotivational syndromes can perform behaviours when prompted by others but experience difficulty in initiating activities themselves.
Testing volitional generation of behavioural options is challenging in animals. In humans, participants can be tested for their ability to generate as many options as possible for real-life scenarios (for example, "It's a sunny day. What could you do?"). Few studies testing option generation have been performed in clinical populations; however, one has shown that the degree of apathy in individuals with schizophrenia correlated inversely with their ability to generate options 41 . Another study failed to find a relationship between option generation and apathy in individuals with Parkinson's disease but did reveal a strong relationship with apathy scores in healthy people 53 . Option generation tasks are very similar to tests of fluency, an index of (frontal) executive control, raising the possibility that, in some individuals, symptoms of amotivation may be driven by executive dysfunction 54 .
Decision making leading to option selection. Even if the ability to generate options is intact, individuals might experience difficulty in selecting between possible options, especially when a decision made now may affect which decisions are available in the future. Many factors affect such selection, including: subjective valuation of potential outcomes; risk or probability of obtaining the reward (which can lead to probabilistic discounting of the subjective value of a reward); devaluation of rewards due to waiting (known as temporal discounting); and perception of the effort required to gain the reward (leading to effort discounting of reward) 55 . Individuals with Parkinson's disease and apathy are less inclined to make a physical effort for rewards 56 , particularly low levels of reward 57 , than people with Parkinson's disease without apathy. The ability to settle on a choice -rather than vacillate -is also an important aspect of decision making for reward, especially if options are similar in value or numerous. However, this has not been compared in people with and without apathy. In extreme states of amotivation, any effort might be considered too costly, such that no action is performed, regardless of the potential reward.
Anticipation.
Once an individual has selected an option, they typically experience motivational arousal (evidenced by physiological measures such as changes in heart rate or pupil dilation) in anticipation of action and/or reward 58 . For example, people normally show Anergia Loss of energy.
Fatigue
Weariness or diminished ability following mental or physical activity.
Appetitive
Approach or goal-seeking phase of behaviour.
Consummatory
Completion or consummation phase of behaviour.
Learning
Acquisition of information, in this case to alter future behaviour.
Fluency
The number of examples generated of a verbal category (for example, words beginning with the letter F) or a nonverbal category (for instance, different patterns on a dot array using four straight lines).
anticipatory pupil dilatation that scales with potential reward magnitude in advance of making speeded movements to obtain reward. This pupil response is blunted in some patients with apathy 59 (FIg. 2a,b ).
Action and effort. The initiation, maintenance and invigoration of action together constitute part of appetitive behaviour -for example, the locomotor approach of an animal to a potentially rewarding experience, such as food. Appetitive behaviour has been referred to as a measure of 'wanting' (distinct from 'liking'; see below) 23 , although some caution against the use of subjective terms in reference to animal studies.
Tasks used to study appetitive components of behaviour often measure how much physical effort an animal is willing to allocate to obtain a reward. For example, in progressive ratio tasks, the number of lever presses a rat has to make to obtain a set reward progressively increases until the animal reaches its 'breaking point' and is no longer willing to exert further effort 25 . Similarly, in a variation of the T-maze, rodents must decide between scaling a barrier to obtain highly rewarding food and a low-effort, low-reward food option 60 (FIg. 2c) . In humans, effort allocation can be manipulated using the number of button presses, the speed of response or the amount of force exerted to obtain rewards (FIg. 2d-f) . Often, such tasks use choice behaviour as an indication of willingness to exert effort 56, [61] [62] [63] . Fewer studies have examined willingness to allocate cognitive effort. Rodents might, for example, have to choose to opt for a highly demanding attention trial (detect a brief illumination) over a low-demand one (detect a prolonged illumination) to obtain a greater reward 64 . In humans too, researchers have probed willingness to expend mental effort (in tasks that place high demands on attention or working memory) versus physical effort (squeezing tightly on hand-held dynamometers) 65, 66 . These studies have shown both common and dissociable brain region contributions to effort-based decision making for rewards in the cognitive and physical effort domains 65, 66 . One important aspect of effort tasks is that the highly effortful option must be achievable; otherwise, any observed changes in decision making could relate to probability discounting, not effort discounting.
A paradigm commonly used to assess 'wanting' , originally developed in rodents, is Pavlovianinstrumental transfer (PIT). PIT involves three stages: Pavlovian (passive) conditioning pairing an initially neutral stimulus (such as a tone or light) with a rewarding outcome (food); instrumental (active, choice-based) association between an action (pressing a lever) and the rewarding outcome; and, finally, the PIT phase itselfthe presentation of the Pavlovian conditioned stimulus (CS; that is, the tone or light) during instrumental performance -usually during extinction (that is, without delivery of rewarding outcomes). Presentation of the (unrelated) CS causes an invigoration of instrumental responding (known as the PIT effect), and is interpreted as reflecting incentive salience, or wanting 67 . Human analogues of the PIT task have been developed, with some evidence that the PIT effect is attenuated in individuals with depression 68 .
Hedonic impact. Consummatory behaviour refers to the achievement of a goal -for example, eating food. Some refer to this as the 'liking' phase of motivated behaviour 23 . One probe used to index consummatory The clinical syndromes of apathy and anhedonia seem to overlap, sharing some possible underlying mechanisms. In the field of effort-based decision making for reward, several possible processes have been identified, some of which are displayed here. First, before an action is initiated, it might be important to generate potential options for behaviour. These might be self-initiated or cued by changes in the surrounding environment. Next, the possible options need to be evaluated in terms of their costs (effort, time required and associated risks) versus their benefits (potential reward) before an option for behaviour is selected. Anticipation of reward and preparation for action are associated with physiological changes (in heart rate and pupil dilatation) linked to motivational arousal. Premotor and motor mechanisms are engaged to initiate, invigorate and sustain appetitive or approach behaviour. Interacting with the behavioural goal consists of the consummatory phase, which may lead to a positive (hedonic) or negative impact. Finally , learning from outcomes to alter weighting of costs and benefits in subsequent decision making is important for optimizing option selection in the future. In principle, lack of motivation -manifest as apathy or anhedonia -might occur due to dysfunction at any one or more of these stages. The reward on offer is announced at the beginning of each trial, before the saccade target is presented. b | On this task , participants' pupils normally dilate more with greater anticipated reward (after the auditory cue announcing maximum reward on offer). Reward sensitivity of the pupils is blunted in individuals with Parkinson's disease (PD) and apathy compared with individuals with PD but without apathy 59 . Shaded area represents standard error of the mean. c | Rodent T-maze experiments reveal that depletion of dopamine in the nucleus accumbens or lesions of the anterior cingulate cortex shifts rats from a strategy of working hard for large rewards (scaling an obstacle, indicated by dashed line, to obtain the large reward) to opting for a smaller reward that requires far less effort 60, 90 . d | An effort task that requires human participants to select between low or high physical effort options (number of button presses) associated with different levels of reward 61 . e | Effort task in which human participants decide to accept or reject offers in which different levels of reward are available for different levels of physical effort (grip force). The image on the screen displays the reward on offer (depicted as the number of apples on a tree) and the force required to obtain that level of reward (indicated by the height of the yellow line on the tree trunk). f | On this task , the likelihood of accepting offers increases with reward on offer and decreases with increasing effort required 46 . Parts a and b are adapted from ReF. behaviour in animal models is the sucrose preference test: rodents given the choice between water and dilute sucrose solution develop a preference for the latter. Animals that have been exposed to chronic mild stress (a model of depression) show decreased preference for sucrose 69 , taken to indicate reduced hedonic capacity. Direct pleasure from the consummatory phase of behaviour has also been indexed by the facial expressions of rodents and primates in response to sweet versus bitter substances 23 . However, several studies in humans suggest that hedonic aspects of the consummatory phase (measured by self-reported pleasure in response to sweet tastes) may be intact in people with schizophrenia with pronounced negative symptoms 24 or MDD 70 , raising the question of how appropriate decreased liking (as assessed through sucrose preference or facial expression) in rodents is as a model of anhedonia in humans.
Learning. Finally, an important aspect of effort-based decision making for reward is how individuals learn from the outcomes of their actions to guide future selections. This concept is known as reinforcement learning -that is, how rewards or losses associated with a stimulus or an action alter subsequent behaviours through updates to stimulus value. Learning can be assessed by examining how choices change over time in response to feedback. In early work, this was often achieved by analysing performance on early versus late trials in, for example, the Iowa gambling task 71 , revealing differences between patient groups and healthy volunteers in terms of poorer learning of the most rewarding selections over time 72 . However, the interpretation of such differences is challenging, as several processes could potentially contribute (including option selection, hedonic impact and learning). A fruitful alternative approach to data analysis that has gained popularity in recent years is to use computational modelling 73 .
Computational modelling
Computational models (BoxeS 2,3) leverage the richness of observed data (for example, patterns of behaviour that evolve on a trial-by-trial basis) to provide insight into which processes are important in driving individual differences 51 .
For example, a difficult, partially rewarded perceptual task was developed to examine anhedonia. The task revealed reliable, replicable differences in what the authors call reward responsiveness (which measures the bias towards selecting the stimulus more frequently associated with reward) between control participants and individuals with depression 74 . However, alterations in several processes -including learning, reward valuation or simply perceptual discrimination -could potentially contribute to this reward responsiveness measure.
Application of a computational model (similar to that in Box 3) to a large number of data sets produced Computational models have increasingly been applied to tasks assessing motivation and decision making. In contrast to standard ('descriptive') data analyses, computational approaches start by creating a generative model that includes the processes thought to be involved in task performance, specified in a mathematically precise form (an example is shown in Box 3) . models usually contain a number of free parameters, each of which governs the influence of a specific process on information processing and behavioural output. Parameters are estimated from the data and can often capture patterns that would not be immediately evident from a descriptive analysis (for example, patterns that evolve over time during learning). The estimated parameters can be used to summarize the data alongside traditional descriptive measures as they can distil large amounts of information and are hypothesized to relate to specific cognitive processes 73 . Uncertainty estimates can also be generated for each parameter at the individual subject level. . The estimation process also produces a measure of model fit. often, several different model architectures will be compared (model selection), with parameters extracted from the winning model. To avoid overfitting, the fit of a model is balanced against its complexity (which is related to the number of free parameters). Parameters across several models can also be averaged, which can be useful if data from different individuals are best fit by different models (although this makes sense only if models are structurally similar).
Model fitting
A crucial process is model checking -that is, testing whether the model faithfully reproduces the observed datawhich may, in turn, lead to the construction of a better model. It is also important to check how accurately parameters can be recovered; this involves generating data from the model using known parameters, which should then be estimable. If parameter recovery fails, the model requires revision.
Limitations of the computational approach
There are certain limitations of the computational approach to consider 170 . First, although modern desktop computers can quickly implement simple models and estimation methods (for example, maximum likelihood), more complex procedures (such as sampling) can be slow and thus not very practical. Second, parameters can be interpreted in multiple ways. For example, the inverse temperature parameter (β in Box 3) of the softmax function can be interpreted in terms of consistency, exploration or valuation, limiting the interpretation of such models. Third, even simple models can contain redundant parameters, which can result in poor estimation. Fourth, as with any statistical analysis, larger data sets will tend to favour more complex models. This point limits the utility of model comparison, as which model is favoured will depend in part on the amount of data included in the model. Indeed, some investigators eschew model comparison altogether, advocating a model-checking approach 171 .
Iowa Gambling task
A neuropsychological test of decision making for reward.
Reward responsiveness
The development of a bias towards a more frequently rewarded stimulus.
Overfitting
When a model becomes too complex (has too many parameters) and begins to describe random error in the data rather than the relationships between variables.
Inverse temperature parameter
A constant in the softmax decision rule. It affects the steepness of the function around the inflexion point, resulting in more consistent choices at higher values. a clearer interpretation: symptoms of anhedonia were associated not with differences in incremental learning or perceptual discrimination but instead with blunted expected value of reward at the time of decision 75 ( FIg. 1) . In a different context, computational modelling of data from a reinforcement learning task in individuals with schizophrenia again revealed an apparent sparing of incremental learning, with the overall level of poor performance predominantly accounted for by impairments of working memory (which can be important in learning tasks owing to the time delay between stimuli and outcomes) 76 . Thus, the use of computational models in these studies helped to dissect the different cognitive processes involved in reward tasks, showing that learning per se is apparently spared in anhedonia, and that instead differences in behaviour
Incremental learning
Learning over trials.
Box 3 | Example of a simple computational model
The example below assumes that participants perform a task in which two stimuli, A and B, are associated with high and low probabilities of reward, respectively 172 . Participants must learn the contingencies and select the high-probability reward stimulus to perform well. A common way of modelling this type of task is to specify a learning rule (how stimulus or action values are updated over time) and a decision rule (how decisions are made based on those associations).
Learning rule (value updating)
learning rules are often based on the prediction error -the discrepancy between actual and expected outcomes 116 
:
δ r t v t = ( )− ( )
δ is the prediction error, which can be positive or negative (better or worse than expected, respectively). r(t) is the reward outcome (0 or 1) received on trial t. v(t) is the value of the choice, which depends on the strength of the stimulus-outcome association and thus varies over the experiment, and which evolves over time (depicted in part a of the figure) . The model then updates the value:
v t v t α δ ( + 1) = ( ) + * (2)
The stimulus value for a new trial is equal to its value on the previous trial, plus the prediction error δ weighted by α, the learning rate parameter. In other words, α specifies the degree of influence of the prediction error. α can be interpreted as the speed of learning, or the influence of recent outcomes -the higher the α value, the stronger influence of recent outcomes. Part a of the figure shows the effect of varying the value of α (different coloured lines) on value learning over 50 trials, of which 80% are rewarded and 20% not rewarded (at identical points in the game).
Decision rule (choosing options based on value)
When modelling decision making, one possible assumption would be that the higher-value stimulus is always chosen. However, in reality, organisms rarely behave in this manner and instead occasionally explore low-value options. one decision rule that incorporates the occasional opting for the lower-value option uses the softmax function 173 . Computational modelling has also demonstrated that improvements in apathy scores in individuals with Parkinson's disease who were taking dopaminergic medication were associated with greater reward sensitivity (that is, the expected value of reward) but not with changes in effort sensitivity 56 . Conversely, healthy individuals taking a selective serotonin-reuptake inhibitor produced more effort, which modelling revealed to be due to reduced effort costs, rather than increases in reward sensitivity 77 . Although to date there has been little systematic use of modelling in this field, these examples show how using a computational approach can illuminate how specific cognitive processes map onto different symptom profiles and treatments.
p v t v t v t (A) = exp ( β* ( ) ) ( exp ( β* ( ) ) + exp ( β* ( ) ))
Brain regions
Reports of previously well people suddenly developing profound amotivation following strokes or other focal lesions have implicated a set of brain regions that seem to be crucial for motivated behaviour in humans 78 . These include the basal ganglia (particularly ventral aspects including the globus pallidus and ventral striatum (vStr)), parts of the anterior cingulate cortex (ACC) and the ventromedial prefrontal cortex (vmPFC), which is often referred to as medial orbitofrontal cortex (OFC) 32, [79] [80] [81] [82] [83] . Early experimental DBS studies in people institutionalized for psychiatric disorders reported that they might gain pleasure from self-stimulation of electrodes implanted in the septal region, which included the nucleus accumbens (NAc) -part of the vStr -and ventral pallidum 84 . However, a more scrutinous assessment suggested that stimulation might in fact have led to patients merely wanting to engage in more pleasurable activities 85 . More recent human DBS studies show that ACC stimulation can induce the expectation of an imminent challenge that the patient feels determined to overcome 86 . Furthermore, DBS of the subgenual ACC was suggested to ameliorate symptoms of depression in some individuals who had been resistant to treatment with drugs 87 , although a larger trial did not find a significant effect of such stimulation 88 .
Findings from many investigations in animals also converge on a pivotal role in motivation for a network of brain regions that includes ventral basal ganglia structures (including the NAc and ventral pallidum), the ACC, the ventral tegmental area (VTA) and the basolateral amygdala (BLA) 26, 85 (FIg. 3) . The VTA is the source of widespread dopamine (DA) projections to the vStr (known as the mesolimbic DA system); to the ACC and the PFC (the mesocortical DA system); and to the amygdala.
Reward and effort valuation. In rodents, lesions of the NAc or ACC, disconnection of the NAc from the ACC or inactivation of the BLA or BLA-ACC connections can all profoundly affect motivation, with reduced willingness to allocate effort for rewards [89] [90] [91] [92] . In monkeys too, injection of bicuculline (a GABA receptor antagonist) into the vStr and putamen reduces the frequency of self-initiated actions to collect reward 93 . By contrast, classical intracranial self-stimulation studies -and, more recently, optogenetic methodshave revealed that rodents will choose to work in order to receive stimulation of the VTA, of the medial forebrain bundle (which includes the mesolimbic DA pathway) or of parts of the lateral and posterior hypothalamus 94, 95 . One pioneering study combined optogenetic stimulation with functional MRI (fMRI) and electrophysiological recordings in rats (FIg. 4) . Stimulation of the medial prefrontal cortex (mPFC) reduced reward-seeking behaviour, assessed for example by sucrose preference. mPFC stimulation also blunted the striatal activation and reward seeking elicited by optogenetic stimulation of VTA DA neurons; animals that preferred places where they received VTA stimulation no longer did so when the mPFC was simultaneously stimulated 95 . The authors consider this to be a potential model for anhedonic behaviour.
A recent meta-analysis of human fMRI studies has suggested that whereas the vmPFC, vStr and midbrain regions including the VTA preferentially signal reward, the ACC and the anterior insula are key nodes that signal effort 51 . Activation of the ACC and/or the supplementary motor area (SMA) occurs when people perform effortbased decision-making tasks 46, [96] [97] [98] . One study reported that the level of dorsomedial frontal activation during the decision-making phase was positively correlated with behavioural apathy scores in healthy individuals 46 . This finding might indicate that people who are more apathetic are confronted by a greater brain-energetic cost when making cost-benefit decisions about whether the physical effort required is worth the reward on offer; that is, when they perform a subjective valuation of a potential reward. Intriguingly, disruption of activity in the SMA -but not in the primary motor cortexusing transcranial magnetic stimulation also leads to a decrease in perceived effort level 99 ; therefore, this region might be a crucial node in the evaluation of effort allocation.
Integration of reward and effort signals.
Several neuroimaging studies in healthy humans have attempted to examine the basis of cost-benefit decision making when effort is required to obtain rewards 51 (FIg. 1) . Activation of the vStr or pallidum varies positively with the magnitude of prospective reward and, in some reports, has been reported to be negatively modulated by prospective effort, revealing an interaction between reward and effort signals 65, 96, 100 . ACC activity is positively correlated with the degree of physical effort but negatively related to reward 46, 97, 101 . Thus, some authors argue that the ACC plays a key role in integrating costs (effort) and benefits (reward) to compute the net value of performing an action 51 . Investigation of cognitive and physical effort has revealed both common and unique brain-activation patterns 65, 66 . One study found that reward devaluation by both types of effort was represented within a common network including the ACC and other dorsomedial frontal regions, the anterior insula and the dorsolateral PFC 66 . Importantly, activation in these 'domain-general' regions also co-varied positively with effort and negatively with reward, suggesting that these parameters might be integrated within these areas. By contrast, activity within the amygdala seemed to reflect processing of the value of rewards associated specifically with cognitive effort.
Option selection and option generation. Intriguingly, when people have to select from reward-effort combinations, the activation of ACC or SMA corresponds to the difference in reward or effort levels of the chosen and unchosen options 98 . This finding suggests that these dorsomedial frontal regions might be important for option selection after the valuation of the potential behavioural options that are presented to an individual (FIg. 1) . Which brain regions are involved in self-generated options for behaviour remains to be established, but some data point to a role of the pre-SMA and possibly the dorsolateral prefrontal cortex 102, 103 .
Brain regions in apathy and anhedonia. Neuroimaging studies across various human neurodegenerative conditions have revealed that apathy is strongly associated with atrophy of or functional disruption of the dorsal ACC (dACC), vmPFC or OFC, vStr and VTA, as well as brain regions connected to these areas 27 . Intriguingly, work examining neural correlates of anhedonia in patients with depression has implicated a largely convergent network of brain regions that show blunted activation, relative to controls, when performing tasks involving appetitive, cost-benefit decision and consummatory or learning phases of reward processing. In depression, activation is reduced in regions including the vStr, caudate, vmPFC or OFC and dACC (although contradictory results were reported in the dACC in different studies) [104] [105] [106] . Although the precise pattern of regions observed to show blunted responses in depression is not identical across studies, some of this inconsistency is attributable to clinical heterogeneity (with frequent reports that the degree of blunting correlates with the severity of anhedonic symptoms 104 ) and the use of different paradigms. For example, a recent investigation reported no differences between depressed and nondepressed groups in reward-prediction error signals in the vStr 107 , part of learning from outcomes (FIg. 1) , in contrast to earlier findings using different fMRI paradigms [104] [105] [106] . 
Reward-prediction error
A computational quantity indicating the difference between expected and actual outcomes.
The results from investigations in adults with depression discussed above are consistent with a large study of motivational processing in a predominantly healthy community sample of adolescents (of whom a minority experienced clinical depression), which identified a robust inverse relationship between vStr activation during the anticipatory phase of reward processing (FIg. 1) and depressive symptoms, especially anhedonia (FIg. 3b) , as well as future risk of depression 108 . A similar picture is evident during the anticipatory phase in studies of anhedonic individuals with schizophrenia 109 , although the ubiquitous use of antipsychotic medications, which block DA transmission, complicates their interpretation. A meta-analysis of 33 studies in depression and 24 studies in schizophrenia (with paradigms tapping several of the processes depicted in FIg. 1) concluded that reward-related responses were reliably blunted in the caudate, putamen and ACC in both diagnoses 110 .
Neuromodulators A large literature exists on the effect of pharmacological manipulations of neurotransmitters on motivational processing in animals. Other investigations have correlated motivation with monoamine neurotransmitter release, measured using microdialysis or fast-scan cyclic voltammetry (FSCV) concurrently with behaviour 111 . Some studies have manipulated midbrain monoaminergic neurons directly using optogenetic methods 95 . Dopamine in animal studies. The first evidence for a role of DA in motivation came from findings that depleting DA -using the neurotoxin 6-hydroxydopamine (6-OHDA) -led to robust reductions in instrumental conditioned responding (an aspect of sustaining effort; FIg. 1 ) that were reversed by amphetamine (which enhances DA signalling) 112, 113 . Later, direct microinjections of DA agonists and antagonists into the NAc of rats revealed, respectively, increases and decreases in conditioned reinforcement 114 . Similar manipulations also affect performance in the same direction on PIT 67 and effort expenditure tasks 26, 115 : for example, DA antagonists reduce vigour and preference for high-efforthigh-reward options, suggesting that DA profoundly influences the decision and action phases of reward processing.
Importantly, hedonic responses during the receipt of primary reward (that is, during the consummatory phase of reward processing; FIg. 1) are not affected by DA in rats 67 but are altered by opiate manipulation 23 . More recent work shows that adenosine A 2A receptor antagonists can reverse deficits in effort allocation produced by several interventions (for example, DA receptor antagonists or tetrabenazine, a drug that depletes DA), potentially by acting on adenosine A 2A receptors that colocalize with DA D 2 receptors in the striatum and NAc 26 .
There is also good evidence that DA is involved in learning (FIg. 1) , with an influential study showing that phasic DA neuron firing in the midbrain temporally corresponds to the evolution of reward-prediction errors 116 (Box 2). This finding has since been confirmed using optogenetic methods 117, 118 and has led to a proposed distinction between the functions of tonic DA signals, which are proposed to play a primary role in encoding action and effort, and phasic DA signals, which are hypothesized to influence reward learning 115, 119 . However, the dichotomy between tonic and phasic DA has been challenged by FSCV findings. When rats navigate mazes to retrieve rewards, NAc DA signals ramp up slowly as animals come closer to their goals (action and anticipation; FIg. 1) , scaling with reward magnitude 111 . These DA ramping signals might represent the estimated expected value of reward, which in turn might be used in cost-benefit decisions to evaluate
Primary reward
Rewarding stimuli that facilitate survival of an organism or its offspring, such as food, water and sex. whether it is worth engaging in effortful activity 120 . Intriguingly, DA release seems to be contingent on action (and therefore effort), not just valuation, because when rats perform a rewarded go/no-go task, DA signals are attenuated when animals must inhibit movement to obtain a reward 121 . Together, these findings suggest that the tonic-phasic DA hypothesis might require revision, and that instead a unitary account, in which phasic signals simultaneously influence both valuation and learning, might provide a better explanation for the role of DA in reward processing 122 -with phasic DA signals before choice affecting valuation and propensity to deploy effort, and those during consummation affecting learning 120 . Dopamine in human studies. Human psychopharmacology studies have been largely consistent with the evidence linking DA to effort-based decision making for reward in animals 123 . Dietary depletion of DA precursors, which reduces DA synthesis 124 , attenuates participants' sensitivity to rewards during decision making 125 and also increases punishment learning relative to reward learning 126 , with some reporting corresponding reductions in reward-elicited blood-oxygen-level-dependent (BOLD) responses in the striatum 127 . Research using DA receptor antagonists to block transmission has yielded less consistent results, possibly owing to doses used and the actions of these compounds on other monoamine systems and inhibitory autoreceptors 123 . l-DOPA (l-3,4-dihydroxyphenylalanine; which increases DA synthesis), amphetamine and methylphenidate (which block DA reuptake) and D 2/3 receptor agonists generally increase several of the aspects depicted in FIg. 1 . Despite the clear evidence that DA transmission, especially in the striatum, has a central role in controlling motivated behaviour, standard pharmacological treatments for depression do not target the DA system 132 . To our knowledge, besides a few pilot studies of agomelatine 133 (an atypical antidepressant that disinhibits DA release through its action on serotonin 5-HT 2c receptors), there has never been a trial specifically focused on treating anhedonia. However, a D 2/3 receptor agonist, piribedil, was reported to be successful in treating apathy in DBS-treated individuals with Parkinson's disease who subsequently have their DA drug dose reduced 134 . Dopaminergic drugs also enhance effort-based decision making in Parkinson's disease by boosting reward sensitivity 56, 57 . Finally, a cholinesterase inhibitor has also been reported to confer improvement in apathy in Parkinson's disease, although whether this is via effects on effort-based decision making has not been established 135 . Interestingly, ketamine, which antagonizes NMDA receptors and is effective in treatment-resistant depression (in which anhedonia is common) 136 , has profound facilitatory downstream effects on DA transmission 137 . Ketamine has also been reported to be effective in ameliorating anhedonia over and above general depressive symptoms, with reductions in anhedonia associated with increases in resting-state metabolism in the vStr and ACC 138 . Further studies are needed to investigate whether ketamine can improve symptoms of amotivation in disorders besides treatment-resistant depression.
A few studies have linked DA to motivational symptoms in individuals with neurological and psychiatric disorders using positron emission tomography (PET). In depression, striatal D 2/3 receptor binding was negatively correlated with anhedonia 139 . In Parkinson's disease 140 and anhedonic depression 141 , there is also a negative relationship between striatal DA transporter binding and amotivation, and in cannabis users, apathy is associated with low DA synthesis capacity 142 . These attenuations of DA function may in part be caused by chronic inflammation 143 , which is common in disorders in which fatigue, anhedonia and apathy are prominent 144 .
Serotonin in animal studies. The other major neurotransmitter linked to motivation is serotonin (5-HT). A common finding from neurophysiological studies is that there are opponent interactions between 5-HT and DA 145 . For example, drugs acting at the 5-HT 2C receptor can modulate DA release from neurons of the mesolimbic and mesocortical pathways. The 5-HT 2C receptor antagonist SB-242084 increases the number and duration of effortful responses that rats will make for food rewards; this observation could be explained by changes in either the decision-making or action phases of reward processing 146 (FIg. 1) .
One influential computational account -based in part on evidence that 5-HT plays a role in inhibiting action in the face of aversive stimuli 147 and in learned helplessness 148 (in which motivational responding is reduced) -has hypothesized that DA signals prediction errors for reward whereas 5-HT signals those for punishment (that is, part of learning 149 ; FIg. 1 ). More recent theoretical formulations propose a more nuanced picture, suggesting that 5-HT may promote Pavlovian (reflexive) inhibitory control (which could be related to either decision making or action) 150 . Empirical research has suggested that a simple relationship between 5-HT and aversive processing is an oversimplification 151 . Recordings made directly from neurons in the dorsal raphe nucleus (DRN), a major source of 5-HT neurons, show that firing is modulated by the size of upcoming reward (related to anticipation; FIg. 1 ), similar to the pattern observed in DA neurons 152 , although with considerable heterogeneity among DRN neurons, which are not all serotonergic. Optogenetic stimulation of identified 5-HT DRN neurons results in increased patience for rewards delivered after a cued delay (part of decision making 153 ; FIg. 1) . Other optogenetic studies stimulating DRN neurons report that stimulation is reinforcing and elicits a greater propensity to exert effort (again, reflecting part of decision making; FIg. 1) . However, this effect is not solely related to 5-HT release as some of the stimulated DRN neurons were glutamatergic 154 .
Serotonin in human studies. Pharmacological manipulations of 5-HT in humans have provided some consistent effects. Dietary depletion of a 5-HT precursor reliably results in reduced behavioural inhibition in the face of potential punishment (that is, disinhibition, reflecting increased vigour 155 ; FIg. 1 ), a conclusion supported by neuroimaging 156 . Other reports show that 5-HT precursor depletion reduced representation of expected reward value during decision making in a learning task (as assessed using computational modelling) 157 and reduced the speed of responding for reward 158 (part of action; FIg. 1 ). Another investigation in healthy volunteers (also discussed in the Computational modelling section above) demonstrated that both acute and chronic administration of a selective serotonin-reuptake inhibitor affected decision making, reducing effort costs but not reward valuation 77 (FIg. 1) . Notably, apathy in Parkinson's disease has been associated with low 5-HT transporter binding, which some researchers interpret as a measure of neuronal integrity, in vStr and ACC 159 . However, in general, the role of 5-HT in motivation is far from clear and requires substantial further empirical work.
Summary. Extensive investigations have suggested that the DA and 5-HT systems modulate several aspects of effort-based decision making for rewards. However, the findings do not suggest that there is a simple mapping of each of these neurotransmitter systems to the components identified from behavioural studies (FIg. 1) . Rather, the results seem to suggest more complex involvement of these neuromodulators, and very few studies to date have examined their interaction with one another in shaping motivated behaviour. These considerations have implications for development of new therapies for apathy and anhedonia. Given the complexity of each behavioural syndrome -with dissociable component processes and potentially different patterns of behavioural deficit across individuals labelled as having the same syndrome -it seems unlikely that a single drug therapy would be appropriate for all patients.
Conclusions
This Review of diverse sets of data from human and animal model experiments reveals some of the mechanisms that might be involved in the genesis of apathy and anhedonia, and provides a framework for developing potential treatments. To move forward, it seems crucial to establish which underlying brain mechanisms contribute to a syndrome of amotivation, such as apathy or anhedonia, in an individual patient. Using clinical definitions might not be sufficient to capture these (see also ReF. 24 ), as different constellations of disrupted mechanisms might occur in different individuals. Moreover, the pattern of deficits need not be disease specific. Hence, future research will need to focus on elucidating the mechanisms that underpin a behavioural syndrome.
As we have seen, anhedonia and apathy are strongly related across different disorders when both have been measured using clinical scales 36, 39, 40 . However, there is not a perfect overlap; therefore, the question arises as to which mechanisms might be common to both and which might be unique to each of these syndromes. The development of new questionnaires provides one way to address this question. One of them now attempts to distinguish between anticipatory and consummatory aspects of motivation but has not always been useful in making distinctions between these two processes in clinical groups 160 . However, it must be borne in mind that these are subjective assessments that do not necessarily provide the granularity required.
Perhaps a better way to establish whether there are any fundamental differences between apathy and anhedonia might be to fractionate behaviour and examine underlying components, such as those delineated in FIg. 1 . To improve phenotyping in this way would require a battery of behavioural paradigms, ideally combined with computational modelling (BoxeS 2,3) . To investigate whether dysfunction of the same brain regions underlies the disruptions of reward-related behaviour observed across brain disorders would require the application of a core battery of functional imaging tasks across clinical diagnoses.
Although both apathy and anhedonia are clinically debilitating and have a profound impact on quality of life, there have been few attempts to develop pharmacological treatments 132 . This seems an area ripe for investigation, given the clear clinical need and close correspondence between behavioural tests developed for humans and animal models. The results of pharmacological modulation and stimulation in rodent models have revealed the complexity of neurotransmitter involvement in motivated behaviour. Nevertheless, they provide hope that it might be possible to develop treatments targeted to components of effort-based decision making for reward. Such efforts might be relevant to psychological therapies as well. For example, behavioural activation therapy for depression, which specifically targets goal-directed behaviour, can be as effective as cognitive behavioural therapy 161 . In addition, several psychosocial interventions, including cognitive behavioural therapy or exercise therapy, seem to be modestly effective in treating negative symptoms in schizophrenia, although better-controlled studies are required to establish their efficacy 162 . These considerations suggest that for further progress in this field, it is essential to understand the mechanisms underlying the 'surface manifestations' of apathy and anhedonia -the clinical presentation -and to characterize the phenotype more carefully in individual cases. The ultimate aim would be to use this framework to develop personalized treatments -pharmacological or psychological -for patients suffering from debilitating motivational symptoms.
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Behavioural activation therapy
A psychological therapy that focuses on activity scheduling to encourage patients to approach activities that they avoid and on analysing processes (for example, rumination) that serve as forms of avoidance.
Cognitive behavioural therapy
A psychological therapy that aims to assist a person to change their thinking and behaviour by practising effective strategies to decrease symptoms and distress.
